A Boring Biotech That’s Too Cheap to Ignore

One insider even bought $2 million in shares. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

"ARDX is cheap, growing and has a commercial catalyst in place for 2026." Karim Rahemtulla, Co-Founder, Monument Traders Alliance One of the trends Bryan and I have been following closely is biotech. The insider buying activity in this sector is becoming impossible to ignore. And one stock that keeps coming up on my radar is Ardelyx (ARDX) – a play I recently got positioned on in The War Room. ARDX has two commercial drugs – IBSRELA for irritable bowel syndrome and ZPHOZAH for chronic kidney disease. I know, not exactly cocktail party conversation. But ARDX's fundamentals caught my eye. Right now, the biotech group is projecting $500 million in sales in the year ahead, driven by the two new drugs in the early stages of a commercial ramp. It's also making smart commercial moves to drive growth. This week, ARDX announced a marketing partnership with the Ladies Professional Golf Association (LPGA), aiming to raise awareness of irritable bowel syndrome and constipation, a condition that disproportionately affects women. More awareness means more patients, and more patients means more prescriptions. Plus, with a market cap of just under $2 billion, ARDX is currently trading at about 4 times sales. That's actually cheap for a young growth company – and here's why that matters. SPONSORED The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion. Click here to see the Tesla shock that could blindside everyone. When large pharma companies acquire smaller biotechs, they typically pay premiums of 10x sales or more. That's the kind of upside I look for. And perhaps the strongest signal – insiders are buying. Last week, company chairman David M. Mott bought 333,333 shares of the company for an estimated $1,946,331. Any time a high-ranking official puts nearly $2 million of his own money on the table – I take notice. I'll be diving deeper into more insider buy activity in this afternoon's Trade of the Day issue – stay tuned. Action Plan: Biotech is one of our highest-conviction sectors for 2026, and ARDX is just one piece of the puzzle. Bryan and I recently recommended 3 biotech stocks in our latest Monument Trend Advisory report. To unlock those picks and get access to all our trend reports each month, click below to join us today. Click here to unlock Monument Trend Advisory. SPONSORED Back, After 46 Years - The Rogers Trade From 1973-1980, Jim Rogers' Quantum Fund delivered a staggering 4,200% return during one of the most powerful commodity cycles in history. We're now seeing conditions that closely resemble that same setup in gold - and traders who recognize it early could have multiple asymmetric opportunities ahead. Register free for the 20x Gold Window event Wednesday, March 4 at 1 p.m. ET Monument Traders Alliance, LLC   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2026 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201. REF: 000147203048

Share on Facebook

Share on Twitter

Share on Google+

Share on LinkedIn

Subscribe to receive free email updates: